JO
DCOY

John Overdeck’s Decoy Therapeutics DCOY Stock Holding History

John Overdeck’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$19.8K – 3242
2023
Q1 		$19.8K Buy
+7
New +$22.5K ﹤0.01% 2852
2022
Q1 		– Sell
-3
Closed -$45K – 4149
2021
Q4 		$45K Buy
3
+2
+200% +$52.9K ﹤0.01% 4144
2021
Q3 		$20K Buy
+1
New +$34.5K ﹤0.01% 4168
2020
Q4 		– Hold
0
– -$10K – 3720
2020
Q3 		– Hold
0
– – – 3010
2016
Q1 		– Hold
0
– -$311K – 3093
2015
Q4 		– Hold
0
– – – 2226

Other funds holding DCOY

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John Overdeck's DCOY Position: Q2 2023 in Review

John Overdeck sold out of Decoy Therapeutics (DCOY) in Q2 2023, closing a stake of 7 shares — an estimated $19.8K sold.

John Overdeck first reported a position in DCOY in Q3 2021 and held it in 3 quarters. The position peaked at $45K in Q4 2021. 9 funds tracked by Wall St. Rank hold DCOY as of Q2 2023.

  • John Overdeck reported no remaining Decoy Therapeutics position as of Q2 2023 after selling out during the quarter.
  • John Overdeck sold 7 Decoy Therapeutics shares in Q2 2023, an estimated $19.8K.
  • John Overdeck first reported a position in Decoy Therapeutics in Q3 2021 and held it in 3 quarters.
  • John Overdeck's Decoy Therapeutics position peaked at $45K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.